The estimated Net Worth of John M Climaco is at least $670 Tysiąc dollars as of 1 February 2024. Mr Climaco owns over 166,666 units of Cns Pharmaceuticals Inc stock worth over $34,508 and over the last 13 years he sold CNSP stock worth over $0. In addition, he makes $635,100 as Chairman i CEO & Pres at Cns Pharmaceuticals Inc.
Sign up
Mr D CNSP stock SEC Form 4 insiders trading
Mr has made over 7 trades of the Cns Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 166,666 units of CNSP stock worth $50,000 on 1 February 2024.
The largest trade he's ever made was buying 166,666 units of Cns Pharmaceuticals Inc stock on 1 February 2024 worth over $50,000. On average, Mr trades about 5,119 units every 95 days since 2012. As of 1 February 2024 he still owns at least 215,676 units of Cns Pharmaceuticals Inc stock.
You can see the complete history of Mr Climaco stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. John Michael Climaco Esq., J.D. biography
John Michael Climaco Esq., J.D. is the Chairman, CEO & Pres at Cns Pharmaceuticals Inc.
What is the salary of Mr D?
As the Chairman i CEO & Pres of Cns Pharmaceuticals Inc, the total compensation of Mr D at Cns Pharmaceuticals Inc is $635,100. There are no executives at Cns Pharmaceuticals Inc getting paid more.
How old is Mr D?
Mr D is 52, he's been the Chairman i CEO & Pres of Cns Pharmaceuticals Inc since . There are 2 older and 1 younger executives at Cns Pharmaceuticals Inc. The oldest executive at Cns Pharmaceuticals Inc is Dr. Donald H. Picker Ph.D., 75, who is the Chief Science Officer.
What's Mr D's mailing address?
John's mailing address filed with the SEC is C/O CNS PHARMACEUTICALS, INC., 100 WEST LOOP SOUTH, SUITE 900, HOUSTON, TX, 77027.
Insiders trading at Cns Pharmaceuticals Inc
Over the last 5 years, insiders at Cns Pharmaceuticals Inc have traded over $132,960 worth of Cns Pharmaceuticals Inc stock and bought 509,021 units worth $458,622 . The most active insiders traders include Christopher Downs, John M Climaco oraz Waldemar Priebe. On average, Cns Pharmaceuticals Inc executives and independent directors trade stock every 79 days with the average trade being worth of $6,051. The most recent stock trade was executed by Jerzy Gumulka on 1 February 2024, trading 33,333 units of CNSP stock currently worth $10,000.
What does Cns Pharmaceuticals Inc do?
cns pharmaceuticals, inc., a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. the company's lead drug candidate is berubicin, which completed phase i clinical trial that is used for the treatment of glioblastoma multiforme. it has license agreements with houston pharmaceuticals, inc. and the university of texas m.d. anderson cancer center; and a development agreement with wpd pharmaceuticals inc. cns pharmaceuticals, inc. was founded in 2017 and is based in houston, texas.
What does Cns Pharmaceuticals Inc's logo look like?
Complete history of Mr Climaco stock trades at Digirad Corp, Moleculin Biotech Inc, Perma-Fix Environmental Services, InfuSystem Inc oraz Cns Pharmaceuticals Inc
Cns Pharmaceuticals Inc executives and stock owners
Cns Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
John Michael Climaco Esq., J.D.,
Chairman, CEO & Pres -
Christopher S. Downs CPA, CTP, FP&A,
Chief Financial Officer -
Dr. Sandra L. Silberman M.D., Ph.D.,
Chief Medical Officer -
Dr. Donald H. Picker Ph.D.,
Chief Science Officer -
Dr. Waldemar Priebe Ph.D.,
Founder & Chairman of the Scientific Advisory Board -
Amy Mahery,
Director -
Biosciences, Inc. Cortice,
-
Christopher Downs,
Chief Financial Officer -
Jerzy Gumulka,
Director -
Carl Anthony Evans,
Director -
Jeffry R. Keyes,
Director -
John M Climaco,
Chief Executive Officer -
Waldemar Priebe,
-
Faith L. Charles,
Director -
Bettina M. Cockroft,
Director